Supply Chain

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and bolster domestic supply chain resilience amid rising tariffs and reshoring investments.

The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.

The pact introduces a 15% levy on most EU exports, including pharmaceuticals.

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential future impacts for gene therapy regulation and market access.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.

The growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such as S&OP and S&OE.

The Zensights Federated Healthcare Advisory Panel explores how shifting global dynamics are reshaping access and strategic planning across the healthcare system.

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Brett Casper explores the marketplace complexities that manufacturers face regularly.

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

The formula for future-proofing pharmaceutical networks to withstand any disruption.

Eli Lilly CEO David Ricks to the BBC: “It feels like it'll be hard to come back from here."

Three of the new sites will focus primarily on producing ingredients for domestic usage.

Prescription data between 2017 and 2023 revealed that while Adderall prescription fills decreased following the shortage, many children transitioned to alternative stimulants for attention-deficit/hyperactivity disorder.

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

To safeguard patient access to life-saving medications, pharma companies must prioritize building robust resilience strategies that encompass IT systems, inventory management, risk mitigation, and regulatory compliance.

The Federal Trade Commission and Department of Health and Human Services are examining the practices of group purchasing organizations and drug wholesalers and the role they may play in triggering shortages of generic medications.

Beyfortus (nirsevimab-alip), a monoclonal antibody that protects against respiratory syncytial virus-associated lower respiratory tract disease, experienced higher than anticipated demand that led to shortages during the 2023-2024 season.

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

Lack of trust in pharma-provided content proves to be a key barrier to successful engagement, highlighting issues like promotional spin, information availability, and more.

Law aims to mitigate ongoing global drug shortages.

Researchers highlight steps to be taken in the European Union to manage the challenge of ongoing drug shortages.

IQVIA report explores why these shortages are increasing, and how they can be mitigated.